eBook Checkpoint Responses in Cancer Therapy (Cancer Drug Discovery and Development) download
by Wei Dai
Author: Wei Dai
Publisher: Humana Press; 2008 edition (June 6, 2008)
ePub: 1490 kb
Fb2: 1283 kb
Other formats: lrf docx doc lit
Subcategory: Medicine and Health Sciences
Series: Cancer Drug Discovery and Development.
DUI Checkpoint: 5 things cops CAN'T make you do - Продолжительность: 2:09 Shouse Law Group Channel Recommended for you. 2:09. Nora Fatehi - Reaction To Garmi Song Street Dancer 3D - Продолжительность: 12:57 Nora Fatehi Recommended for you. Новинка! 12:57.
However, it is becoming increasingly clear that RB is not only involved in the etiology and progression of cancer, but also modifies the response to specific therapeutic modalities
Targeting the p53/MDM2 Pathway for Cancer Therapy. DNA Topoisomerases as Targets for the Chemotherapeutic Treatment of Cancer. Bender, Ryan P. (et a.
on novel bioactive compounds, analogs, targets & predictive biomarkers & drug efficacy biomarkers.
Checkpoint Responses in Cancer Therapy. We attempt to summarize recent developments in this field and discuss the structural characteristics of the Plk family that appear to make them uniquely suitable for cancer drug discovery and development. Protein tyrosine kinases have served as targets for successful cancer drug development. Protein serine/threonine (Ser/Thr) kinases are more prevalent than protein tyrosine kinases among the molecular entities that regulate cell proliferation. They have been extensively explored to determine their effectiveness as targets for discovery of novel anticancer agents.
Today's anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets.
Cancer drug discovery and development has long been a priority for the National Cancer Institute, most . Historically, NCI has played a vital role in cancer drug discovery and development, and, today, that role continues
Cancer drug discovery and development has long been a priority for the National Cancer Institute, most importantly in areas of need that are not being adequately addressed by the private sector. Historically, NCI has played a vital role in cancer drug discovery and development, and, today, that role continues. Frequently, NCI’s drug development efforts focus on unmet needs that are not being adequately addressed by the private sector.
Автор: Wei Dai Название: Checkpoint Responses in Cancer Therapy . TodayвЂ™s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets.
Описание: Checkpoint regulation is critical in understanding cancer development and cancer therapy.
It is intriguing that checkpoint pathways are also critical in cancer therapy .
It is intriguing that checkpoint pathways are also critical in cancer therapy to provide an apoptotic stimulus when cellular damage induced by the therapeutic agent is detected by the sensor system. Understanding the intricacies of checkpoint response is, therefore, central to the design of therapeutic regimen that will enhance antitumor effects. The contributions in this book will consolidate the current state of knowledge on checkpoint responses that may lay the foundation for hypothesis-driven rational approaches in advancing the management of cancer. The immediate attraction of the book to.
Extensive research has uncovered a set of molecular surveillance mechanisms – commonly called “checkpoints” – which tightly monitor cell-cycle processes. Today’s anticancer drug development has identified many of these cell-cycle checkpoint molecules as effective targets. Research now promises to uncover a new generation of anticancer drugs with improved therapeutic indices based on their ability to target emerging checkpoint components. Checkpoint Responses in Cancer Therapy summarizes the advances made over the past 20 years, identifying components of cell-cycle checkpoints and their molecular regulation during checkpoint activation and validating the use of checkpoint proteins as targets for the development of anticancer drugs. This book’s distinguished panel of authors takes a close look at topics ranging from the major molecular players affecting DNA synthesis and the response to DNA damage to advances made in the identification of chemical compounds capable of inhibiting individual mitotic kinases. Illuminating and authoritative, Checkpoint Responses in Cancer Therapy offers a critical summary of findings for researchers in the pharmaceutical and biotechnology industries and a valuable resource for academic scientists in cancer research and the study of cell-cycle regulation, signal transduction and apoptosis.